The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: A perspective from different continents

Pain Reports

Volumn 2, Issue 3, 2017, Pages

  Häuser, Winfried ^a   Schug, Stephan ^b,c   Furlan, Andrea D ^d  

^a KLINIKUM SAARBRÜCKEN   (Germany)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d TORONTO REHABILITATION INSTITUTE   (Canada)

Author keywords

Abuse; Addiction; Chronic noncancer pain; Guidelines; Misuse; Mortality; Opioids

Indexed keywords

EID: 85045035059     PISSN: None     EISSN: 24712531     Source Type: Journal    
DOI: 10.1097/PR9.0000000000000599     Document Type: Conference Paper

References (60)

1. Anderson T. The politics of pain. BMJ 2010;341:c3800.
2. Arzneimittelkommission der deutschen Ärzteschaft (Drug Commission of the German Medical Association). UAW-News International Die unkritische Anwendung von Fentanylpflastern erhöht das Risiko für schwerwiegende Nebenwirkungen (The uncritical use of fentanyl patches increases the risk of serious adverse events. Dtsch Ärztebl 2012;109: A724–725.
3. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349:1943–3.
4. Blanch B, Pearson SA, Haber PS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol 2014;78:1159–66.
5. Brennan F, Cousins MJ. Pain relief as a human right. Pain Clinical Updates 2004;12:1–4.
6. Brouwers M, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna SE, Littlejohns P, Makarski J, Zitzelsberger L; AGREE Next Steps Consortium. On behalf of the AGREE Next Steps Consortium: AGREE II: Advancing guideline development, reporting and eval uation in healthcare. J Clin Epidemol 2010;63:1308–11.
7. Burke DS. Forecasting the opioid epidemic. Science 2016;35:529.
8. Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. Practicetoolkits. Available at: www.nationalpaincentre.mcmaster.ca/documents/practicetoolkit.pdf. Accessed December 1, 2016.
9. CDC guideline for prescribing opioids for chronic pain—United States, 2016. Available at: https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm. Accessed December 1, 2016.
10. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O’Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113–30.
11. Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, Green JL. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015;372:241–8.
12. Degenhardt L, Gisev N, Cama E, Nielsen S, Larance B, Bruno R. The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. Pharmacoepidemiol Drug Saf 2016;25:521–38.
13. Deutsche Schmerzgesellschaft. Guideliens initiated by the German Pain Society. Long-term opioid therapy for chronic non-cancer pain. Available at: www.dgss.org/versorgung/leitlinien-zur-schmerzbehandlung/von-derdeutschen-schmerzgesellschaft-ev-initiierte-leitlinien. Accessed December 1, 2016.
14. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009;18:891–6.
15. Drug commissary of the German government. Drug report 2015. Available at: www.drogenbeauftragte.de. Accessed December 1, 2016.
16. Dunn KM, Saunders KW, Rutter CM. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152:85– 92.
17. European Monitoring Center for Drugs and addiction. European drug report 2016. Available at: http://www.emcdda.europa.eu/system/files/publications/2637/TDAT16001DEN.pdf. Accessed December 1, 2016.
18. Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists (FPMANZCA). Recommendations regarding the use of opioid analgesics in patients with chronic non-cancer pain. Available at: http://fpm.anzca.edu.au/documents/pm1-2010.pdf and http://fpm. anzca.edu.au/documents/4462_001.pdf. Accessed December 1, 2016.
19. Fanelli G, Tölle TR, DE Andrés J, Häuser W, Allegri M, Montella S, Kress HG. Opioids for chronic non-cancer pain: a critical view from the other side of the pond. Minerva Anestesiol 2016;82:97–102.
20. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162–73.
21. Fischer B, Keates A, Bühringer G, Reimer J, Rehm J. Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world? Addiction 2014;109:177–81.
22. Fischer F, Lange K, Klose K, Greiner W, Kraemer A. Barriers and strategies in guideline implementation-a scoping review. Basel: Healthcare, 2016;4:pii E36.
23. Furlan AD, Reardon R, Salach L. The opioid manager: a point-of-care tool to facilitate the use of the Canadian Opioid Guideline. J Opioid Manag 2012;8:57–61.
24. Furlan AD, Reardon R, Weppler C; National Opioid Use Guideline Group. Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ 2010;182:923–30.
25. Gomes T, Mamdani MM, Dhalla IA, Cornish S, Paterson JM, Juurlink DN. The burden of premature opioid-related mortality. Addiction 2014;109:1482–8.
26. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011;171:686–91.
27. Hamunen K, Laitinen-Parkkonen P, Paakkari P, Breivik H, Gordh T, Jensen NH, Kalso E. What do different databases tell about the use of opioids in seven European countries in 2002? Eur J Pain 2008;12:705–15.
28. Häuser W, Bernardy K, Maier C. Long-term opioid therapy in chronic noncancer pain. A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks. Schmerz 2015;29:96–108. Erratum in: Schmerz 2015;29:309.
29. Häuser W, Bock F, Engeser P, Hege-Scheuing G, Hüppe M, Lindena G, Maier C, Norda H, Radbruch L, Sabatowski R, Schäfer M, Schiltenwolf M, Schuler M, Sorgatz H, Tölle T, Willweber-Strumpf A, Petzke F. Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain. Schmerz 2015;29:109–30.
30. Häuser W, Petzke F, Radbruch L, Tölle TR. The opioid epidemic and the long-term opioid therapy for chronic noncancer pain revisited: a transatlantic perspective. Pain Manag 2016;6:249–63.
31. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465–74.
32. International Association for the Study of Pain. Declaration of Montréal. Declaration that access to pain management is a fundamental human right. Available at: www.iasp-pain.org/DeclarationofMontreal?navItemNumber5582. Accessed December 1, 2016.
33. Karanges EA, Blanch B, Buckley NA, Pearson SA. Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. Br J Clin Pharmacol 2016;82:255–67.
34. Kipping K, Maier C, Bussemas HH, Schwarzer A. Medication compliance in patients with chronic pain. Pain Physician 2014;17:81–94.
35. Leece P. Update on health Canada project: family physicians & opioid prescribing. Available at: http://www.cpso.on.ca/CPSO/media/documents/Methadone/Presentations/16Nov25_Leece-Pamela.pdf. Accessed February 18, 2016.
36. Maier C, Schaub C, Willweber-Strumpf A, Zenz M. Long-term efficiency of opioid medication in patients with chronic non-cancer-associated pain. Results of a survey 5 years after onset of medical treatment. Schmerz 2005;19:410–17.
37. Manchikanti L, Helm S II, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV. Opioid epidemic in the United States. Pain Physician 2012; 15:ES9–38.
38. Marschall U, L’hoest H, Radbruch L, Häuser W. Long-term opioid therapy for chronic non-cancer pain in Germany. Eur J Pain 2016;20:767–76.
39. Moisset X, Trouvin AP, Tran VT, Authier N, Vergne-Salle P, Piano V, Martinez V. Use of strong opioids in chronic non-cancer pain in adults. Evidence-based recommendations from the French Society for the Study and Treatment of Pain. Presse Med 2016;45:447–62.
40. Müller-Schwefe G. Aktionsprogramm Schmerz. Z Angew Schmerzth 1998;4:1. Available at: www.schmerz-therapie-deutschland.de/pages/zeitschrift/z4_98/art_401.htm. Accessed December 1, 2016.
41. Naliboff BD, Wu SM, Schieffer B, Bolus R, Pham Q, Baria A, Aragaki D, Van Vort W, Davis F, Shekelle P. A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain. J Pain 2011;12:288–96.
42. Nielsen S, Bruno R, Degenhardt L, Stoove MA, Fischer JA, Carruthers SJ, Lintzeris N. The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. Med J Aust 2013;199:696–9.
43. Novak SP, Håkansson A, Martinez-Raga J, Reimer J, Krotki K, Varughese S. Nonmedical use of prescription drugs in the European Union. BMC Psychiatry 2016;16:274.
44. Nuckols TK, Anderson L, Popescu I, Diamant AL, Doyle B, Di Capua P, Chou R. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 2014;160:38–47.
45. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010;363: 1981–5.
46. Pain & Policy Studies Group, University of Wisconsin/WHO Collaborating Center, International Narcotics Control Board. World Health Organization population data 2015. Available at: http://www.painpolicy.wisc.edu/countryprofiles. Accessed December 1, 2016.
47. Petzke F, Welsch P, Klose P, Schaefert R, Sommer C, Häuser W. Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015;29:60–72. Erratum in: Schmerz 2015;29:308.
48. Rintoul AC, Dobbin MD, Drummer OH, Ozanne-Smith J. Increasing deaths involving oxycodone, Victoria, Australia, 2000-09. Inj Prev 2011;17:254–9.
49. Robertson A, Hitzig SL, Furlan AD. An evaluation of the performance of the Opioid Manager clinical tool in primary care: a qualitative study. J Opioid Manag 2014;10:187–99.
50. Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Aust 2011;195:280–4.
51. Schaefert R, Welsch P, Klose P, Sommer C, Petzke F, Häuser W. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015;29:47–59.
52. Schmiedl S, Rottenkolber M, Hasford J, Rottenkolber D, Farker K, Drewelow B, Hippius M, Saljé K, Thürmann P. Self-medication with over-the-counter and prescribed drugs causing adverse-drug-reaction-related hospital admissions: results of a prospective, long-term multi-centre study. Drug Saf 2014;37:225–35.
53. Schneeweiss S, Hasford J, Göttler M, Hoffmann A, Riethling AK, Avorn J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 2002;58:285–91.
54. Schubert I, Ihle P, Sabatowski R. Increase in opiate prescription in Germany between 2000 and 2010: a study based on insurance data. Dtsch Arztebl Int 2013;110:45–5.
55. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, Boers M. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009;62:1013–20.
56. Shield KD, Jones W, Rehm J, Fischer B. Use and nonmedical use of prescription opioid analgesics in the general population of Canada and correlations with dispensing levels in 2009. Pain Res Manag 2013;18:69–74.
57. Sommer C, Welsch P, Klose P, Schaefert R, Petzke F, Häuser W. Opioids in chronic neuropathic pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 2015;29:35–46.
58. Svendsen K, Borchgrevink P, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med 2011;25:725–32.
59. The Ontario Drug Policy Research Network. Opioid use and related adverse events in Ontario. 2016. Available at: http://odprn.ca/wpcontent/uploads/2016/11/ODPRN-Opioid-Use-and-Related-Adverse-Events-Nov-2016.pdf. Accessed February 20, 2017.
60. Werber A, Marschall U, L’hoest H, Hauser W, Moradi B, Schiltenwolf M. Opioid therapy in the treatment of chronic pain conditions in Germany. Pain Physician 2015;18:E323–31.